CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 10,400 Shares of Company Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel James Kasinger sold 10,400 shares of the firm’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $60.24, for a total value of $626,496.00. Following the completion of the transaction, the general counsel owned 94,784 shares of the company’s stock, valued at approximately $5,709,788.16. This represents a 9.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

CRISPR Therapeutics Trading Down 0.1%

NASDAQ:CRSP opened at $55.70 on Friday. CRISPR Therapeutics AG has a 52-week low of $44.12 and a 52-week high of $78.48. The company has a quick ratio of 17.85, a current ratio of 17.85 and a debt-to-equity ratio of 0.34. The stock has a fifty day simple moving average of $53.63 and a 200-day simple moving average of $52.75. The company has a market capitalization of $5.39 billion, a PE ratio of -11.70 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. The business had revenue of $10.18 million during the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. On average, equities research analysts expect that CRISPR Therapeutics AG will post -4.47 earnings per share for the current fiscal year.

Institutional Trading of CRISPR Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Capital International Investors lifted its stake in shares of CRISPR Therapeutics by 4.3% during the 4th quarter. Capital International Investors now owns 5,892,745 shares of the company’s stock worth $309,016,000 after purchasing an additional 243,487 shares during the period. Geode Capital Management LLC grew its position in shares of CRISPR Therapeutics by 5.0% in the fourth quarter. Geode Capital Management LLC now owns 2,249,223 shares of the company’s stock valued at $117,971,000 after purchasing an additional 108,053 shares during the period. Norges Bank purchased a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at $25,706,000. Swiss National Bank increased its stake in CRISPR Therapeutics by 5.1% in the first quarter. Swiss National Bank now owns 169,700 shares of the company’s stock valued at $8,073,000 after purchasing an additional 8,200 shares during the last quarter. Finally, Affinity Asset Advisors LLC acquired a new position in CRISPR Therapeutics in the first quarter valued at $7,136,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Analyst Upgrades and Downgrades

CRSP has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating on shares of CRISPR Therapeutics in a report on Monday, August 31st. Needham & Company LLC reissued a “buy” rating and issued a $82.00 price target on shares of CRISPR Therapeutics in a report on Monday, August 31st. Citigroup reissued a “market outperform” rating on shares of CRISPR Therapeutics in a report on Tuesday, August 25th. Citizens Jmp restated a “market outperform” rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, August 31st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, CRISPR Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $67.94.

Key CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Casgevy sales momentum remains a key bullish factor. An analysis highlighted 78% sequential sales growth for Casgevy in the second quarter, reinforcing the therapy’s potential as a major commercial product and supporting a long-term bullish view of CRSP despite a slow initial launch. CRISPR Therapeutics: Why AI Giant Anthropic’s Discovery Has Rocked Gene Editing
• Positive Sentiment: Institutional interest provides additional support. Fisher Asset Management reported a new position of 77,960 CRSP shares, valued at approximately $4.25 million at the end of the second quarter. The purchase is an older filing and does not necessarily reflect current positioning, but it signals that some professional investors see upside potential. Billionaire Ken Fisher Was Buying These 2 Cathie Wood Stocks
• Positive Sentiment: Analyst optimism remains substantial. One market commentator sees a potential path to roughly 85% upside, citing CRSP’s position in gene-editing medicine and Casgevy’s commercial opportunity. However, the target is speculative and must be weighed against the company’s ongoing cash burn and losses. CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines using CRISPR/Cas9 technology. The company’s programs are designed to modify disease-associated genes in human cells, with the goal of treating serious conditions across hematology, oncology, autoimmune disease and regenerative medicine.

Its most advanced product is Casgevy (exa-cel), an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals. Casgevy uses CRISPR/Cas9 gene editing to modify a patient’s blood stem cells and is approved in several markets for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.